A Multi-National Trial Evaluating Safety and Efficacy Including Pharmacokinetics, of NNC 0129-0000-1003 when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia (Protocol No. NN7008-3859)

Service: Trial Number:
Principal Investigator: Conducted at:
Miller Children's & Women's Hospital Long Beach
Currently enrolling additional patients:
Age Range:
7 years & up

The purpose of this research trial is to investigate the efficacy and safety of a new Factor VIII product called N8-GP for patients with Hemophilia A, factor VIII deficiency. The study consists of two treatment options. One option is a preventive treatment plan in which N8-GP is given in a vein every 4th day to prevent bleeding episodes. The second treatment option is to give the intravenous infusion of N8-GP as needed for bleeding episodes requiring treatment. A total of approximately 115 patients are expected to complete this study worldwide from approximately 75 hemophilia centers.

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
The email to associate with this registration.